Morning Wealth



Thursday, 17th August, 2017

Nifty Futures	Level 1	Level 2	Level 3
Resistance	9930	9990	10020
Support	9880	9810	9770

Indices (NSE)	Close	Pts. Chg	% Chg
Nifty	9,897.3	103.2	1.0
Nifty Future (Aug)	9,905.0	89.4	0.9
Nifty Future (Sep)	9,937.6	90.7	0.9
Bank Nifty	24,437.7	322.0	1.3
CNX100	10,250.0	105.8	1.0
CNX500	8,635.7	94.2	1.1
CNX Midcap	18,088.7	235.0	1.3

Indices (BSE)	Close	Pts. Chg	% Chg
Sensex	31,770.9	321.9	1.0
BSE-100	10,273.2	106.1	1.0
BSE-200	4,312.1	45.3	1.1
BSE-500	13,660.0	147.3	1.1
Mid Cap	15,282.3	189.7	1.2
Small Cap	15,611.7	202.5	1.3

Sectoral Indices	Close	Pts. Chg	% Chg
BANKEX	27,572.8	344.0	1.2
CAPITAL GOODS	17,255.5	-21.9	-0.1
REALTY	2,094.8	17.3	0.8
POWER	2,275.2	9.1	0.4
OIL & GAS	14,615.5	51.3	0.4
METAL	12,932.0	218.6	1.7
CD	17,623.3	54.8	0.3
AUTO	23,987.2	382.1	1.6
TECK	5,773.0	22.9	0.4
IT	10,262.4	51.2	0.5
FMCG	10,029.8	243.8	2.5
HEALTHCARE	13,214.8	123.9	0.9
VIX	14.2	-0.1	-1.0

Exchange	Advance	Decline	Unchg
BSE	1,635	949	121
NSE	1,143	534	79

Volume	Rs (in cr)	% Chg
NSE Cash	26,122.1	9
BSE Cash	4,401.8	41
NSE F&O	849,969.8	131

Net Inflows/Outflows (Rs in cr)	Buy	Sell	Net
FII	5,399.9	6,489.9	-1,090.1
DII	3,569.7	2,232.8	1,336.9

Intraday Nifty Outlook

Index continued its up move for second consecutive day. Index earlier has formed Morning Doji star a bullish reversal candlestick pattern which suggests recent trough to act as strong support and index can see a pullback. Index has reversed after taking support at lower trend line of the broadening wedge which is a bullish signal for short term trend. RSI has formed positive reversal with price which is a bullish signal and compliments the bullish view of price. Going ahead index has immediate resistance at 9930, a sustenance above this level will continue the pullback towards 9990-10060 while support comes at 9880-9810.

Corporate News

Petronas keen to buy stake in IOC's LNG terminal

Malaysian state-owned oil and natural gas producer Petronas is keen to buy a stake in Indian Oil Corporation's under-construction 5-million tonne a year LNG import terminal at Ennore. Petroliam Nasional Bhd, or Petronas, is the second firm after Petronet LNG Ltd, India's biggest liquefied natural gas (LNG) importer, to have expressed interest in taking a stake in the Ennore plant. "Petronas has expressed interest in taking a stake," IOC Chairman Sanjiv Singh told reporters here. "Nothing has been finalised so far. It's at a preliminary stage as of now." IOC holds 95 per cent stake in the Rs. 5,151-crore Ennore LNG import terminal, which is expected to be completed by June 2018. Tamil Nadu Industrial Development Corporation (TIDCO) has 5 per cent. The state-owned refiner wants to retain a minimum 50 per cent stake in the project and so, practically 45 per cent stake is available for the taking. "There is Petronas and then, there is Petronet which has also expressed interest. We have to see what fits our business," he said. Singh, however, clarified that mere taking equity will not guarantee any company of a proportionate capacity on the import terminal. "Capacity booking (for import of own LNG cargoes) is separate than equity stake. They are two different things," he said. While Petronas may be looking at Ennore as a market to sell the global portfolio of LNG it has, IOC is likely to retain a major say to bring its own gas. (Source - Business line)

Zydus Cadila gets USFDA nod for BP drug

Cadila Healthcare today said its group firm Zydus Cadila has received final approval from the US health regulator to market blood pressure drug, Tiadylt ER. The approval by the US Food and Drug Administration (USFDA) for diltiazem hydrochloride (Tiadylt ER) extended release capsules is for multiple strengths of 120mg, 180mg, 240mg, 300mg and 420mg, Cadila Healthcare said in a BSE filing. "The drug will be manufactured at the group's formulations manufacturing facility at pharma SEZ in Ahmedabad," it added. Besides blood pressure, diltiazem hydrochloride is also prescribed for angina and certain heart rhythm disorders, it added. Cadila Healthcare further said the group has also received final approval from the USFDA to market azelastine hydrochloride 137 mcg nasal pray, which is used in treatment of runny nose, sneezing and post nasal drip caused by allergies. The spray will be produced at the group's formulations manufacturing unit at Moraiya, Ahmedabad. With the latest approvals from the USFDA, the group now has more than 140 approvals and has so far filed over 300 abbreviated new drug applications. (Source: Business line)

Biocon withdraws application for EU approval of two drugs

Biocon Ltd has withdrawn its application seeking European Union approval for two drugs after the EU drugs regulator sought re-inspection of their production facility, sending shares down more than 8 per cent. Biocon will re-submit the applications for breast cancer drug Trastuzumab and Pegfilgrastim, which cuts infection risk in patients undergoing chemotherapy, after the European Medicines Agency completes the inspection, it said in a stock exchange filling on Wednesday. "The European regulatory authorities had informed us of the need for a re-inspection of our drug product facility for these products," Biocon said, without specifying when the regulator would carry out the inspection. "We are on track to complete our corrective action and preventive actions by the end of this quarter, and it is our intent to seek re-inspection and re-submission thereafter." (Source - Business line)



Morning Wealth

Nifty Top 5 Gain- ers	Close	Pts. Chg	% Chg
TECHM	420.0	17.8	4.4
TATAMOTORS	389.3	13.9	3.7
CIPLA	590.5	20.4	3.6
BANKBARODA	147.2	4.9	3.4
TATAPOWER	82.1	2.5	3.1

Nifty Top 5 Los- ers	Close	Pts. Chg	% Chg
ASIANPAINT	1141.3	-12.7	-1.1
NTPC	170.1	-1.7	-1.0
YESBANK	1761.9	-16.7	-0.9
POWERGRID	220.7	-2.1	-0.9
INFY	975.2	-6.3	-0.6

Int. Indices	Close	Pts. Chg	% Chg
S&P 500	2,468.1	3.5	0.1
DOW	22,024.9	25.9	0.1
NASDAQ	6,345.1	12.1	0.2
FTSE	7,433.0	49.2	0.7
DAX	12,263.9	86.8	0.7
CAC	5,176.6	36.4	0.7
NIKKEI	19,714.9	-14.4	-0.1
Hangseng	27,359.2	-49.8	-0.2
Straits Times	3,260.3	-18.6	-0.6

ADR	Close	Pts. Chg	% Chg
HDFC Bank	96.2	0.5	0.6
ICICI Bank	9.3	0.2	2.5
Infosys	15.7	0.2	1.0
TATA Motors	30.1	0.6	2.0
Wipro	6.1	0.0	-0.7

Currencies	Close	Pts. Chg	% Chg
Dollar Index	93.4	-0.1	-0.2
USD/INR	64.2	0.0	0.0
EURO/INR	75.1	-0.6	-0.7
USD/YEN	109.8	-0.9	-0.8

Commodities	Close	Pts. Chg	% Chg
Gold (spot) Rs	28,952.0	-128.0	-0.4
Silver (spot) Rs	38,863.0	-315.0	-0.8
Crude (Brent) \$	50.5	0.2	0.4
Crude Oil (WTI) \$	46.9	0.1	0.2

Economy

Falling bids may cast a shadow on solar projects

It's not entirely good news that bids for solar projects are falling because they may leave developers with little financial buffer to face challenges such as cost overruns and counter-party delays. Grid curtailment risk, which may be temporary, is also a concern as renewable energy penetration increases. Falling solar panel prices and rising competition have led to aggressive bidding. The increase in panel conversion efficiency has contributed to a reduction in the land required for panels and a fall in the balance of system cost. According to an India Ratings and Research (Ind-Ra) analysis, a tariff of ₹2.44/kWh could have an equity internal rate of return of 10 per cent. Against the backdrop of distribution utilities trying to reduce power purchase costs, the emerging threat of renegotiation and termination of power purchase agreements can derail developments in the sector. The Rewa bid started this trend of risk allocation in tenders and has taken centre stage in bids. Tenders floated consciously address payment security and grid curtailment to attract low bids. Solar Energy Corporation of India and NTPC has witnessed low bids from developers because of the comfort derived from their credit profiles. The pace of solar capacity auctions, along with an emphasis on compliance with renewable purchase obligations, is critical. On the other hand, rooftop solar capacity installation is lagging behind ground-mounted installation owing to limited effort to achieve targets, the report stated. Payments days across counter-parties, except Tamil Nadu's distribution utility, have been observed at less than 90 days. In this backdrop, investor perception of the longterm sustainability of the renewables sector and the fast-changing industry dynamics has affected their appetite for rupee bonds. (Source: Business line)

International News

Asian Tech Stocks Rally; Yen Gains, Dollar Falls

Asian stocks outside of Japan rose, led by technology shares after stellar earnings at Internet giant Tencent Holdings Ltd. The yen jumped and the dollar extended a decline after Federal Reserve meeting minutes reduced the odds of another U.S. interest rate increase this year. Shares in Australia and South Korea advanced, while they swung between gains and losses in Japan and Hong Kong. The Australian dollar added to gains seen in the wake of a rally in basemetal prices, after faster-than-forecast local jobs growth last month. Australian government bond yields tracked a retreat in U.S. yields after a majority of Fed officials stuck with a forecast that inflation would gradually rise to a 2 percent target over the medium term, according to minutes from the July meeting. However, "many" saw some "likelihood" that it would remain below that level for longer than expected. The swaps market sees a reduced chance for a December U.S. interest-rate hike. The minutes didn't specify when the Fed would begin shrinking its balance sheet this year. The tumult that swept markets in the wake of heightened tensions between the U.S. and North Korea last week has eased, bringing down gauges of equity and bond volatility and repairing most of the damage done to stock markets. Attention will now turn to the European Central Bank, which is due to release minutes of its last policy meeting on Thursday, amid signs the euro-area economy gathered pace in the second quarter, led by Germany and Spain. Policy makers have signaled that they are getting closer to phasing out quantitative easing. (Source: Bloomberg)

Major Bulk Deal (NSE)

	Scrip Name	Qty	Туре	Client Name	Trade Price
	SINTEX INDUS- TRIES	3,180,144	BUY	MORGAN STANLEY FRANCE SAS	33.1
-	SINTEX INDUS- TRIES	3,443,624	BUY	RUSSEL INVESTMENT COMPANY PLC	33.1

Major Bulk Deal (BSE)

Scrip Name	Qty	Туре	Client Name	Trade Price
MAX FINANCIAL SERVICES LTD.	8,500,000	SELL	MONEYLINE PORTFOLIO INVESTMENTS LTD.	605.0



Morning Wealth

EVENTS CALENDAR

Monday	Tuesday	Wednesday	Thursday	Friday
14-Aug-2017	15-Aug-2017	16-Aug-2017	17-Aug-2017	18-Aug-2017
Results— Apollo Hospitals, INDAG Rubber, MTNL, NESCO	Results –	Results -	Results — Dish TV, Somany Ceramics	Results-
Economic Indicators— Inflation Rate	Economic Indicators –	Economic Indicators–	Economic Indicators-	Economic Indicators– Bank loan growth
US-	US-	US-	US– Jobless Claims	US-
24 Aug 2047	22 Aug 2047	22 Aug 2047	24 Aug 2047	25 Aug 2047
21-Aug-2017	22-Aug-2017	23-Aug-2017	24-Aug-2017	25-Aug-2017
Results—	Results –	Results -	Results —	Results-
Economic Indicators—	Economic Indicators –	Economic Indicators-	Economic Indicators-	Economic Indicators– Forex Results
US-	US-	US-	US– Jobless Claims, Existing sales	US-
28-Aug-2017	29-Aug-2017	30-Aug-2017	31-Aug-2017	1-Sept-2017
Results—	Results –	Results -	Results —	Results-
Economic Indicators—	Economic Indicators –	Economic Indicators–	Economic Indicators-	Economic Indicators– Nikkie PMI
US-	US- Consumer con- fifence	US-	US– Jobless Claims	US-

Green: Corporate Event, Red: Economic Events, Dark Blue: US Events/ UK Events

(Source: Bloomberg and BSE)



Research Desk Tel: +91 22 61596406

Institutional Sales Desk Tel: +91 22 61596403/04/05

Disclaimer Appendix

Analyst (s) holding in the Stock: Nil

Analyst (s) Certification:

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

General Disclaimer

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

Recipients of this material should rely on their own investigations and take their own professional advice. BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Corporate Office:

4th floor, Rustom Bldg, 29, Veer Nariman Road, Fort, Mumbai-400001 Phone- +91 22 6159 6464 Fax-+91 22 6159 6160 Website- www.bpwealth.com Registered Office:

24/26, 1st Floor, Cama Building, Dalal street, Fort, Mumbai-400001

BP Wealth Management Pvt. Ltd. CIN No: U67190MH2005PTC154591

BP Equities Pvt. Ltd.

CIN No: U67120MH1997PTC107392